Sequenom June 15th Short Interest Update

Sequenom (NASDAQ:SQNM) stated gains of 385,602 shares or 2.6% in the short interest. The short interest registered from 14,858,708 on May 31,2016 to 15,244,310 on June 15,2016. In terms of floated shares, the shorted positions stood at 13%. The stock has been averaging 838,088 shares daily in trading and would need 18 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Sequenom (NASDAQ:SQNM): The stock opened at $1.10 on Friday but the bulls could not build on the opening and the stock topped out at $1.15 for the day. The stock traded down to $1.10 during the day, due to lack of any buying support eventually closed down at $1.13 with a loss of -5.04% for the day. The stock had closed at $1.19 on the previous day. The total traded volume was 12,415,991 shares.

The company shares have dropped -61.95% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $3.31 and the one year low was seen on Jun 3, 2016. The 50-Day Moving Average price is $1.08 and the 200 Day Moving Average price is recorded at $1.37.

Sequenom (NASDAQ:SQNM) has tumbled 3.42% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 9.71% in the last four weeks. The stocks have underperformed the S&P 500 by 1.82% during the past week but Sequenom (NASDAQ:SQNM) it has outperformed the index in 4 weeks by 13.03%.

Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *